REGENXBIO's Duchenne Gene Therapy Hits Primary Endpoint, Sets Up 2027 BLA Submission
Event summary
- RGX-202 achieved primary endpoint in Phase III AFFINITY DUCHENNE trial with 93% of patients showing microdystrophin expression above 10% (p<0.0001).
- Statistically significant correlation between microdystrophin expression and functional improvement observed.
- REGENXBIO expects to complete dosing in all 60 patients across pivotal and confirmatory trials by mid-2026.
- Cash position decreased to $150.5M as of March 31, 2026, from $240.9M at year-end 2025.
- FDA lifted clinical hold on RGX-121 for Hunter syndrome, but REGENXBIO filed an appeal of the CRL.
The big picture
REGENXBIO's positive Phase III data for RGX-202 positions it as a potential first-in-class gene therapy for Duchenne muscular dystrophy, a market with limited treatment options. The company's multi-indication strategy in retinal diseases, combined with its internal manufacturing capabilities, could drive long-term growth if key catalysts are met. However, its cash position and regulatory path for other programs remain critical watchpoints.
What we're watching
- Regulatory Pathway
- Whether RGX-202 can secure accelerated approval in 2027 based on current data.
- Cash Runway
- The pace at which REGENXBIO burns through its $150.5M cash position before potential milestone payments.
- Pipeline Progress
- The timing and outcome of topline data for sura-vec in wet AMD and diabetic retinopathy expected in Q4 2026.
Related topics